The Geneva Antibody Facility provides the research community with easy, affordable access to well-characterized recombinant antibodies (rAbs) and stimulates the replacement of poorly characterized animal-derived antibodies to generate improved reproducible data in a collaborative way. This is currently done via 5 main initiatives:
(i) An open-access database of sequenced antibodies (ABCD database), providing an unambiguous identifier for each antibody;
(ii) Low-cost production of rAbs by a spin-off company of the university of Geneva (ABCD antibodies SA);
(iii) A technical journal (Antibody Reports), focusing on the experimental validation and characterization of rAbs;
(iv) Sequencing of hybridomas;
(v) Discovery of new rAbs by phage display.